Kinnate Biopharma (KNTE): Price and Financial Metrics


Kinnate Biopharma (KNTE): $8.27

0.08 (+0.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KNTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KNTE Stock Price Chart Interactive Chart >

Price chart for KNTE

KNTE Price/Volume Stats

Current price $8.27 52-week high $26.05
Prev. close $8.19 52-week low $7.29
Day low $7.59 Volume 184,900
Day high $8.28 Avg. volume 156,084
50-day MA $9.50 Dividend yield N/A
200-day MA $15.71 Market Cap 363.67M

Kinnate Biopharma (KNTE) Company Bio


Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.


KNTE Latest News Stream


Event/Time News Detail
Loading, please wait...

KNTE Latest Social Stream


Loading social stream, please wait...

View Full KNTE Social Stream

Latest KNTE News From Around the Web

Below are the latest news stories about Kinnate Biopharma Inc that investors may wish to consider to help them evaluate KNTE as an investment opportunity.

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Presentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancerSAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it has been selected to deliver an oral presentation of preclinical dat

Yahoo | February 14, 2022

Gabelli Convertible and Income Securities Fund Declares First Quarter Distribution of $0.12 Per Share

RYE, N.Y., February 09, 2022--The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund") declared a $0.12 per share cash distribution payable on March 24, 2022 to common stock shareholders of record on March 17, 2022.

Yahoo | February 9, 2022

Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. Event: 11th Annual SVB Lee

Yahoo | February 7, 2022

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Presentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutationsSAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the

Yahoo | January 19, 2022

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248

Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generat

Yahoo | January 18, 2022

Read More 'KNTE' Stories Here

KNTE Price Returns

1-mo 6.57%
3-mo 0.61%
6-mo -57.61%
1-year -64.78%
3-year N/A
5-year N/A
YTD -53.33%
2021 -55.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8912 seconds.